SynAct Pharma AB (FRA:8F8)

SynAct Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-110.83	-82.4	-215.81	-99.21	-69.3
Depreciation & Amortization	-	0.62	75.34	1.02	0.09
Loss (Gain) From Sale of Assets	-	-0.05	-0.04	-0.01	-
Stock-Based Compensation	-	10.07	7.88	-	-
Other Operating Activities	6.01	0.85	2.09	1	-2.88
Change in Accounts Receivable	-	-19.63	19.87	-19.31	-1.21
Change in Accounts Payable	-	7.33	5.11	0.18	1.44
Change in Other Net Operating Assets	7.49	-5.97	5.39	-1.22	6.87
Operating Cash Flow	-97.33	-89.2	-100.18	-117.56	-65
Investment in Securities	-	-	0.37	0.03	-0.01
Investing Cash Flow	-	-	0.37	0.03	-0.01
Long-Term Debt Repaid	-	-0.6	-0.73	-0.98	-0.08
Net Debt Issued (Repaid)	-	-0.6	-0.73	-0.98	-0.08
Issuance of Common Stock	-	94.14	59.46	228.95	80
Other Financing Activities	90.46	-6.14	-4.75	-27.25	-5.6
Financing Cash Flow	90.46	87.41	53.98	200.71	74.32
Foreign Exchange Rate Adjustments	-0.93	0.61	-0.03	1.06	0.13
Miscellaneous Cash Flow Adjustments	-	-0	-	0	-0
Net Cash Flow	-7.8	-1.19	-45.85	84.25	9.45
Cash Interest Paid	2.38	0.98	0.12	0.12	0.11
Cash Income Tax Paid	-8.16	-8.43	-8.47	-7.86	-4.63
Levered Free Cash Flow	-62.35	-62.5	18.74	-86.61	-43.28
Unlevered Free Cash Flow	-60.82	-61.99	19.24	-86.43	-43.21
Change in Working Capital	7.49	-18.28	30.37	-20.35	7.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.